ACRS Logo

Aclaris Therapeutics, Inc. (ACRS) 

NASDAQ
Market Cap
$230.01M
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
63 of 963
Rank in Industry
4 of 53

Largest Insider Buys in Sector

ACRS Stock Price History Chart

ACRS Stock Performance

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Insider Activity of Aclaris Therapeutics, Inc.

Over the last 12 months, insiders at Aclaris Therapeutics, Inc. have bought $7.11M and sold $0 worth of Aclaris Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Aclaris Therapeutics, Inc. have bought $3.69M and sold $8.65M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Leonard Braden Michael (10 percent owner) — $44.73M. Mehra Anand (director) — $3M. Powell Andrew Kenneth William (director) — $17,955.

The last purchase of 666,666 shares for transaction amount of $1.5M was made by Mehra Anand (director) on 2024‑11‑19.

List of Insider Buy and Sell Transactions, Aclaris Therapeutics, Inc.

2024-11-19Purchasedirector
666,666
0.4477%
$2.25$1.5M+75.11%
2024-08-05Purchase10 percent owner
206,025
0.2901%
$1.24$256,357-3.23%
2024-08-02Purchase10 percent owner
167,544
0.2372%
$1.29$216,400-6.25%
2024-07-31Purchase10 percent owner
100,000
0.1421%
$1.33$132,640-0.48%
2024-07-30Purchase10 percent owner
173,730
0.2425%
$1.30$226,370+1.30%
2024-07-22Purchase10 percent owner
17,716
0.0249%
$1.33$23,557-9.02%
2024-07-19Purchase10 percent owner
6,689
0.0092%
$1.30$8,696-8.33%
2024-07-18Purchase10 percent owner
130,317
0.1816%
$1.30$169,555-7.25%
2024-07-05Purchase10 percent owner
123,017
0.1779%
$1.15$141,3340.00%
2024-07-03Purchase10 percent owner
143,288
0.209%
$1.16$166,0710.00%
2024-07-02Purchase10 percent owner
86,092
0.1239%
$1.14$98,4890.00%
2024-07-01Purchase10 percent owner
107,434
0.1538%
$1.14$122,1850.00%
2024-06-28Purchase10 percent owner
1.2M
1.6972%
$1.12$1.35M0.00%
2024-06-27Purchase10 percent owner
235,000
0.3415%
$1.15$271,3310.00%
2024-06-18Purchase10 percent owner
50,000
0.0708%
$1.13$56,505+7.96%
2024-06-17Purchase10 percent owner
150,000
0.2124%
$1.13$169,500+7.96%
2024-06-14Purchase10 percent owner
345,000
0.5039%
$1.17$402,201+2.97%
2024-06-13Purchase10 percent owner
528,621
0.7614%
$1.15$607,757+1.68%
2024-06-12Purchase10 percent owner
82,579
0.1179%
$1.14$94,140+5.22%
2024-06-11Purchase10 percent owner
1M
1.3531%
$1.08$1.08M+8.04%

Insider Historical Profitability

15.3%
Leonard Braden Michael10 percent owner
14250000
19.9493%
$3.22190
Mehra Ananddirector
710030
0.994%
$3.2231+4.44%
Powell Andrew Kenneth Williamdirector
28863
0.0404%
$3.2230<0.0001%
CHA ALBERTdirector
4191397
5.8678%
$3.2220+71.55%
FMR LLC10 percent owner
2571354
3.5998%
$3.2211+61.56%
Sofinnova Venture Partners VIII, L.P.10 percent owner
2289480
3.2052%
$3.2210+61.56%
RA CAPITAL MANAGEMENT, LLC10 percent owner
2102169
2.9429%
$3.22172+27.75%
Walker Nealdirector
1273202
1.7824%
$3.22111<0.0001%
Flynn James E10 percent owner
964101
1.3497%
$3.2207
SCHIFF ANDREW Ndirector
434455
0.6082%
$3.22112<0.0001%
Ruffo FrankChief Financial Officer
201883
0.2826%
$3.2226<0.0001%
Tullman Stephen A.director
177457
0.2484%
$3.2240<0.0001%
Gordon David N.Chief Medical Officer
147447
0.2064%
$3.2203
Monahan JosephChief Scientific Officer
129724
0.1816%
$3.22012
Ali-Jackson KamilChief Legal Officer
122196
0.1711%
$3.22014
VIVO VENTURES VII, LLC10 percent owner
60972
0.0854%
$3.2225+71.55%
Loerop JamesChief Business Officer
21688
0.0304%
$3.2211
Balthaser KevinChief Financial Officer
15461
0.0216%
$3.2212
Manion Douglas J.Pres and CEO
12800
0.0179%
$3.2220<0.0001%
Molineaux Christopher P.director
7682
0.0108%
$3.2201

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Bml Capital Management Llc$11.65M13.199.4M+1,338.65%+$10.84M8.94
BlackRock$6.45M7.35.2M-11.92%-$872,618.69<0.0001
The Vanguard Group$6.11M6.924.93M+4.39%+$257,198.32<0.0001
D. E. Shaw & Co.$4.07M4.613.28M+69.31%+$1.67M<0.01
Millennium Management LLC$4.06M4.593.27M-5.92%-$255,277.55<0.01
Bain Capital Life Sciences Investors Llc$3.72M4.213M-14.29%-$620,000.000.3
ROCK SPRINGS CAPITAL MANAGEMENT, LP$3.41M3.862.75M-8.17%-$303,800.020.09
Acadian Asset Management$2.65M32.14M-9.19%-$267,701.920.01
Renaissance Technologies$2.08M2.351.67M-4.18%-$90,558.98<0.01
Geode Capital Management$1.94M2.21.57M+12.31%+$212,686.95<0.0001
Two Sigma Advisers LP$1.8M2.041.45M+2.12%+$37,324.00<0.01
State Street$1.66M1.881.34M-3.6%-$61,999.99<0.0001
Two Sigma$1.65M1.871.33M-9.15%-$165,967.82<0.01
Qube Research & Technologies$1.5M1.71.21M-27.84%-$579,879.65<0.01
Deutsche Bank$1.19M1.34957,021+2.46%+$28,489.00<0.01
Citadel Advisors LLC$1.15M1.31930,003-82.74%-$5.53M<0.01
Samsara Biocapital Llc$863,252.000.98696,1710%+$00.14
Gsa Capital Partners Llp$842,000.000.95679,137-57.23%-$1.13M0.07
Fidelity Investments$833,067.000.94671,828+0.17%+$1,381.36<0.0001
AQR Capital$759,134.000.86612,205New+$759,134.00<0.01
Palo Alto Investors Lp$706,592.000.8569,832New+$706,592.000.08
Northern Trust$697,157.000.79562,224-14.77%-$120,791.99<0.0001
Morgan Stanley$609,665.000.69491,666-49.62%-$600,423.29<0.0001
Acuitas Investments, LLC$572,462.000.65461,663New+$572,462.000.3
Aisling Capital Management LP$538,724.000.61434,4550%+$00.18
Charles Schwab$519,974.000.59419,334-3.9%-$21,075.03<0.0001
Jane Street Capital$411,358.000.47331,740+27.89%+$89,721.53<0.0001
Hightower Advisors$386,000.000.44312,614-8.87%-$37,548.73<0.01
Ohio Strs$328,000.000.37264,700+37.15%+$88,846.24<0.01
Frazier Life Sciences Management L P$327,827.000.37264,3770%+$00.02
Man Group Plc$307,117.000.35247,675+144.54%+$181,529.80<0.01
BNY Mellon$288,636.000.33232,771-17.57%-$61,503.99<0.0001
Nuveen$206,653.000.23166,656-62.12%-$338,823.08<0.0001
Goldman Sachs$180,807.000.21145,812-72.01%-$465,084.63<0.0001
Group One Trading$165,950.000.19133,831+73.35%+$70,221.01<0.01
Xtx Topco Ltd$152,644.000.17123,100-67.46%-$316,448.00<0.01
Susquehanna International Group$153,090.000.17123,460-19.63%-$37,384.66<0.0001
T. Rowe Price$137,000.000.15109,767+1.15%+$1,562.62<0.0001
Connor Clark & Lunn Investment Management Ltd$124,959.000.14100,773New+$124,959.00<0.0001
RhumbLine Advisers$120,545.000.1497,220+1.53%+$1,822.68<0.0001
Dimensional Fund Advisors$110,435.000.1389,061-52.51%-$122,129.37<0.0001
Tealwood Asset Management$104,134.000.1283,979New+$104,134.000.02
Deuterium Capital Management Llc$99,191.000.1179,993New+$99,191.000.2
UBS$87,297.000.170,401+258.75%+$62,963.31<0.0001
JPMorgan Chase$86,388.000.169,668+0.14%+$117.80<0.0001
Barclays$85,000.000.168,266-61.2%-$134,041.91<0.0001
Russell Investments Group Ltd$77,837.000.0962,772+5,265.13%+$76,386.21<0.0001
Ameriprise Financial$78,087.000.0962,974-2.76%-$2,214.62<0.0001
AllianceBernstein$74,896.000.0960,4000%+$0<0.0001
BBR Partners$74,400.000.0860,000New+$74,400.000.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.